Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

9CY4

Outward-facing cyclosporine A-bound OATP1B1 with sybody 5 (Sb5)

Summary for 9CY4
Entry DOI10.2210/pdb9cy4/pdb
EMDB information46006
Related PRD IDPRD_000142
DescriptorSolute carrier organic anion transporter family member 1B1, Sybody 5, Cyclosporin A (3 entities in total)
Functional Keywordssolute carrier, sybody, membrane protein, drug-drug interactions, transport protein
Biological sourceHomo sapiens (human)
More
Total number of polymer chains3
Total formula weight96987.11
Authors
Sung, M.W.,Lees, J.A.,Han, S. (deposition date: 2024-08-01, release date: 2025-04-16, Last modification date: 2025-05-21)
Primary citationSung, M.W.,Hu, K.,Hurlimann, L.M.,Lees, J.A.,Fennell, K.F.,West, M.A.,Costales, C.,Rodrigues, A.D.,Zimmermann, I.,Dawson, R.J.P.,Liu, S.,Han, S.
Cyclosporine A sterically inhibits statin transport by solute carrier OATP1B1.
J.Biol.Chem., 301:108484-108484, 2025
Cited by
PubMed Abstract: Members of the Organic Anion Transporter Polypeptides (OATP) are integral membrane proteins responsible for facilitating the transport of organic anions across the cell membrane. OATP1B1 (SLCO1B1), the prototypic OATP family member, is the most abundant uptake transporter in the liver and key mediator of the hepatic uptake and clearance of numerous endogenous and xenobiotic compounds. It serves as a locus of important drug-drug interactions, such as those between statins and cyclosporine A, and carries the potential to enable liver-targeting therapeutics. In this study, we report cryo-EM structures of OATP1B1 and its complexes with one of its statin substrates, atorvastatin, and an inhibitor, cyclosporine A. This structural analysis has yielded insights into the mechanisms underlying OATP1B1-mediated transport of statins and the inhibitory effect of cyclosporine A. These findings contribute to a better understanding of the molecular processes involved in drug transport and offer potential avenues for the development of targeted medications for liver-related conditions.
PubMed: 40199401
DOI: 10.1016/j.jbc.2025.108484
PDB entries with the same primary citation
Experimental method
ELECTRON MICROSCOPY (3.41 Å)
Structure validation

236371

PDB entries from 2025-05-21

PDB statisticsPDBj update infoContact PDBjnumon